April 2020 – Biomapas announced the opening of a new office in Central Asia. The new location in Kazakhstan strengthens Biomapas presence in the CIS region and further improves flexible and reliable clinical, regulatory and pharmacovigilance service delivery to the global life science industry in emerging markets.
As a functional and full outsourcing solution provider, with a new office in Almaty, Biomapas continues to expand its international team and ensures the efficiency of services in 65 countries across 5 continents.
“As a basis of our dedication, to supporting pharma and biotech businesses needs, we are expanding in high recruiting countries to be able to accelerate their product path to the market even further,” said Sebastien Duval, Biomapas CBO. “With our strategic growth in Central Asia, Biomapas is deepening our close bond between our international and local experts, this way strengthening service delivery to our customers with standalone expertise at the regional level.”
Kazakhstan is one of the largest countries in the CIS region serving as a geostrategic link to the emerging markets in Central Asia. Biomapas new office in Kazakhstan is a part of a cohesive service network forming professional service support in high recruiting countries to over exceed the ever-growing demand from the pharmaceutical industry.
“Our customers are at the centre of everything we do, and the decision to strengthen our presence in Kazakhstan was a strategic choice representing their growing needs in high recruiting countries,” said Juozas Buitkus, Biomapas COO. “Our continued growth in the CIS region illustrates the growing demand in the life science industry for global network advantages, coupled with our local professional services experience.”
Biomapas is a functional and full outsourcing solution provider to the global life science industry, with key expertise in Clinical Trials, Regulatory Affairs and Pharmacovigilance. The company has a significant presence across the CEE, Nordic and CIS countries thereby offering fast and reliable patient recruitment for Phase I-IV and medical device clinical trials, while regulatory and pharmacovigilance services are provided across 5 continents. We are committed to customer service and satisfaction.